PharmAla Biotech Logo 800 x 422.png
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27 mars 2024 08h00 HE | PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Signs Sale Agreement with Numinus
26 mars 2024 08h55 HE | PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
P-1 molecular structure
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 mars 2024 10h20 HE | PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
PharmAla Biotech Logo 800 x 422.png
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18 mars 2024 08h55 HE | PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Biotech Logo 800 x 422.png
PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE | PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Biotech Logo 800 x 422.png
PharmAla Data to be Published in ACS Chemical Neuroscience
20 févr. 2024 08h55 HE | PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
PharmAla Biotech Logo 800 x 422.png
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09 févr. 2024 08h10 HE | PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla Biotech Logo 800 x 422.png
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 janv. 2024 10h58 HE | PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla Biotech Logo 800 x 422.png
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25 janv. 2024 12h09 HE | PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License